Radiopharm Theranostics
RADX
5 hedge funds and large institutions have $1.58M invested in Radiopharm Theranostics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
67% more funds holding
Funds holding: 3 → 5 (+2)
0.04% less ownership
Funds ownership: 4.41% → 4.37% (-0.04%)
4% less capital invested
Capital invested by funds: $1.65M → $1.58M (-$72.5K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$79.6K |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$130K |
RADX Hedge Fund Activity: Q2 2025 in Review
5 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q2 2025, worth a combined $1.58M — down 4.4% from $1.65M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new RADX positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $79.6K. The largest seller was Affinity Asset Advisors, cutting an estimated $130K.
- 5 institutional investors held Radiopharm Theranostics (RADX) as of Q2 2025, up from 3 in Q1 2025.
- Funds reported $1.58M of Radiopharm Theranostics stock for Q2 2025, down 4.4% quarter-over-quarter.
- 2 funds opened new Radiopharm Theranostics positions in Q2 2025 and 0 closed out, a net change of +2 holders.
- The largest Radiopharm Theranostics buyer in Q2 2025 was UBS Group, an estimated $79.6K added.
- The largest Radiopharm Theranostics seller in Q2 2025 was Affinity Asset Advisors, an estimated $130K sold.
Based on aggregated 13F filings for Q2 2025.